Versapeutics Inc.

Versapeutics Inc. is a for-profit biotechnology company developing novel therapeutics, including monoclonal antibodies, to treat diseases of the central nervous system such as spinal cord injury, Alzheimer's disease, and other neurodegenerative disorders. Through federal grants from the National Institutes of Health, the company conducts preclinical research and development activities to advance its therapeutic candidates towards clinical trials and potential commercialization.

Specifically, Versapeutics has received funding to support pharmacokinetic, toxicology, and efficacy studies in animal models for its lead clinical candidate Versamab-101, an antibody designed to promote axon regeneration and functional recovery after acute spinal cord injury. Additional NIH grants back preclinical development of Versapeutics' Alzheimer's disease compounds and next-generation spinal cord injury therapies. Across awards, the company provides antibody engineering, cell-based assay development, animal model testing services, and preclinical trial design and coordination. Major funding agencies include National Institute of Neurological Disorders and Stroke through the Extramural Research Programs in the Neurosciences and Neurological Disorders, and National Institute on Aging through the Aging Research program. Partners have included academic research groups such as those at the University of California, San Diego.